Antiangiogenic therapy for high-grade gliomas: current concepts and limitations

Pasquale De Bonis, Giammaria Marziali, Vera Vigo, Simone Peraio, Angelo Pompucci, Carmelo Anile, Annunziato Mangiola

Risultato della ricerca: Contributo in rivistaArticolo in rivista

14 Citazioni (Scopus)


Glioblastoma (GBM) is associated with a high degree of angiogenesis. Therefore, antiangiogenic therapy could have a role in the treatment of this tumor. The currently available treatment approaches acting against angiogenesis are mainly directed toward three pathways: VEGF pathway, VEGF-independent pathways and inhibition of vascular endothelial cell migration. It has been demonstrated that antiangiogenic therapy can produce a rapid radiological response and a decrease of brain edema, without significantly influencing survival. Future studies should consider that: animal models are inadequate and cells used for animal models (mainly U87) are deeply different from patient GBM cells; GBM cells may become resistant to antiangiogenic therapy and some cells may be resistant to antiangiogenic therapy ab initio; and angiogenesis in the peritumor tissue has been poorly investigated. Therefore, the ideal target of angiogenesis is probably yet to be identified.
Lingua originaleEnglish
pagine (da-a)1263-1270
Numero di pagine8
Stato di pubblicazionePubblicato - 2013


  • Antiangiogenic
  • VEGF
  • glioblastoma
  • high-grade glioma


Entra nei temi di ricerca di 'Antiangiogenic therapy for high-grade gliomas: current concepts and limitations'. Insieme formano una fingerprint unica.

Cita questo